Overview

Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This trial studies whether Everolimus is efficacious in treating neurofibromatosis 2.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine
NYU Langone Health
Collaborators:
Novartis Pharmaceuticals
The Children's Tumor Foundation
Treatments:
Everolimus
Sirolimus